**Phase I assessments of first-in-human administration of a novel malaria anti-sporozoite vaccine candidate, R21 in matrix-M adjuvant, in UK and Burkinabe volunteers**

Navin Venkatraman1^&, Alfred B. Tiono2&, Georgina Bowyer1&, Jonathan Powlson1, Katharine A. Collins1, Sam Coulibaly2, Mehreen Datoo1, Daniel Silman1, Alphonse Ouedraogo2, Issa Nébié2, Egeruan Imoukhuede1^, Florian Brod1, Pedro Folegatti1, Emma Dickinson1, Sophie Jamieson1, Edith C. Bougouma2, Daniel Wright1, Duncan Bellamy1, Amidou Diarra2, Carly M. Bliss1, Richard Morter1, Greg Glenn4, Louis F. Fries4, Megan Baker1, Ian Poulton1, Sarah Moyle3, Eleanor Berrie3, Nicola Green3, Ekta Mukhopadhyay3, Nicola Viebig5, Brian Angus6, Alison Lawrie1, Rachel Roberts1, Sarah C. Gilbert1, David J.M. Lewis7, Sodiomon B. Sirima2,8@, Katie J. Ewer1\*@, Adrian V. S. Hill1@.

|  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| **Event** | **Intensity** | **Vaccination 1** | | | | | | | | **Vaccination 2** | | | | | | | | | **Vaccination 3** | | | | | | | |
| **10µg R21/MM** | | **50µg R21/none** | | **50µg R21/MM** | | **2µg R21/MM** | | **10µg R21/MM** | | **50µg R21/none** | | **50µg R21/MM** | | | **2µg R21/MM** | | **10µg R21/MM** | | **50µg R21/none** | | **50µg R21/MM** | | **2µg R21/MM** | |
| **n (%)** | | | | | | | | **n (%)** | | | | | | | | | **n (%)** | | | | | | | |
| 11 | | 4 | | 10 | | 6 | | 10 | | 4 | | 8 | | | 6 | | 10 | | 4 | | 8 | | 6 | |
| **Pain** | **None** | 1 | 9.1% | 1 | 25.0% | 1 | 10% | 3 | 50.0% | 0 | 0% | 1 | 25% | 1 | 12.5% | 4 | | 66.7% | 2 | 20% | 3 | 75% | 2 | 25.0% | 4 | 66.7% |
| **Mild** | 10 | 90.9% | 3 | 75.0% | 7 | 70% | 3 | 50.0% | 10 | 100% | 2 | 50% | 6 | 75.0% | 2 | | 33.3% | 8 | 80% | 1 | 25% | 4 | 50.0% | 2 | 33.3% |
| **Moderate** | 0 | 0.0% | 0 | 0.0% | 2 | 20% | 0 | 0.0% | 0 | 0% | 1 | 25% | 1 | 12.5% | 0 | | 0.0% | 0 | 0% | 0 | 0% | 2 | 25.0% | 0 | 0.0% |
| **Severe** | 0 | 0.0% | 0 | 0.0% | 0 | 0% | 0 | 0.0% | 0 | 0% | 0 | 0% | 0 | 0.0% | 0 | | 0.0% | 0 | 0% | 0 | 0% | 0 | 0.0% | 0 | 0.0% |
| **Redness** | **None** | 10 | 90.9% | 4 | 100.0% | 8 | 80% | 5 | 83.3% | 7 | 70% | 3 | 75% | 5 | 62.5% | 6 | | 100.0% | 4 | 40% | 3 | 75% | 6 | 75.0% | 4 | 66.7% |
| **Mild** | 1 | 9.1% | 0 | 0.0% | 2 | 20% | 1 | 16.7% | 3 | 30% | 1 | 25% | 2 | 25.0% | 0 | | 0.0% | 6 | 60% | 1 | 25% | 2 | 25.0% | 2 | 33.3% |
| **Moderate** | 0 | 0.0% | 0 | 0.0% | 0 | 0% | 0 | 0.0% | 0 | 0% | 0 | 0% | 1 | 12.5% | 0 | | 0.0% | 0 | 0% | 0 | 0% | 0 | 0.0% | 0 | 0.0% |
| **Severe** | 0 | 0.0% | 0 | 0.0% | 0 | 0% | 0 | 0.0% | 0 | 0% | 0 | 0% | 0 | 0.0% | 0 | | 0.0% | 0 | 0% | 0 | 0% | 0 | 0.0% | 0 | 0.0% |
| **Swelling** | **None** | 10 | 90.9% | 4 | 100.0% | 10 | 100% | 5 | 83.3% | 10 | 100% | 4 | 100% | 7 | 87.5% | 6 | | 100.0% | 9 | 90% | 4 | 100% | 8 | 100.0% | 5 | 83.3% |
| **Mild** | 1 | 9.1% | 0 | 0.0% | 0 | 0% | 1 | 16.7% | 0 | 0% | 0 | 0% | 0 | 0.0% | 0 | | 0.0% | 1 | 10% | 0 | 0% | 0 | 0.0% | 1 | 16.7% |
| **Moderate** | 0 | 0.0% | 0 | 0.0% | 0 | 0% | 0 | 0.0% | 0 | 0% | 0 | 0% | 0 | 0.0% | 0 | | 0.0% | 0 | 0% | 0 | 0% | 0 | 0.0% | 0 | 0.0% |
| **Severe** | 0 | 0.0% | 0 | 0.0% | 0 | 0% | 0 | 0.0% | 0 | 0% | 0 | 0% | 1 | 12.5% | 0 | | 0.0% | 0 | 0% | 0 | 0% | 0 | 0.0% | 0 | 0.0% |
| **Itch** | **None** | 9 | 81.8% | 4 | 100.0% | 9 | 90% | 6 | 100.0% | 9 | 90% | 3 | 75% | 6 | 75.0% | 6 | | 100.0% | 7 | 70% | 4 | 100% | 8 | 100.0% | 6 | 100.0% |
| **Mild** | 2 | 18.2% | 0 | 0.0% | 1 | 10% | 0 | 0.0% | 1 | 10% | 1 | 25% | 2 | 25.0% | 0 | | 0.0% | 3 | 30% | 0 | 0% | 0 | 0.0% | 0 | 0.0% |
| **Moderate** | 0 | 0.0% | 0 | 0.0% | 0 | 0% | 0 | 0.0% | 0 | 0% | 0 | 0% | 0 | 0.0% | 0 | | 0.0% | 0 | 0% | 0 | 0% | 0 | 0.0% | 0 | 0.0% |
| **Severe** | 0 | 0.0% | 0 | 0.0% | 0 | 0% | 0 | 0.0% | 0 | 0% | 0 | 0% | 0 | 0.0% | 0 | | 0.0% | 0 | 0% | 0 | 0% | 0 | 0.0% | 0 | 0.0% |
| **Warmth** | **None** | 10 | 90.9% | 4 | 100.0% | 7 | 70% | 6 | 100.0% | 7 | 70% | 3 | 75% | 6 | 75.0% | 6 | | 100.0% | 8 | 80% | 4 | 100% | 5 | 62.5% | 5 | 83.3% |
| **Mild** | 1 | 9.1% | 0 | 0.0% | 3 | 30% | 0 | 0.0% | 3 | 30% | 1 | 25% | 2 | 25.0% | 0 | | 0.0% | 2 | 20% | 0 | 0% | 3 | 37.5% | 1 | 16.7% |
| **Moderate** | 0 | 0.0% | 0 | 0.0% | 0 | 0% | 0 | 0.0% | 0 | 0% | 0 | 0% | 0 | 0.0% | 0 | | 0.0% | 0 | 0% | 0 | 0% | 0 | 0.0% | 0 | 0.0% |
| **Severe** | 0 | 0.0% | 0 | 0.0% | 0 | 0% | 0 | 0.0% | 0 | 0% | 0 | 0% | 0 | 0.0% | 0 | | 0.0% | 0 | 0% | 0 | 0% | 0 | 0.0% | 0 | 0.0% |
| **Fever** | **None** | 11 | 100.0% | 4 | 100.0% | 10 | 100% | 6 | 100.0% | 8 | 80% | 4 | 100% | 8 | 100.0% | 6 | | 100.0% | 10 | 100% | 4 | 100% | 8 | 100.0% | 6 | 100.0% |
| **Mild** | 0 | 0.0% | 0 | 0.0% | 0 | 0% | 0 | 0.0% | 1 | 10% | 0 | 0% | 0 | 0.0% | 0 | | 0.0% | 0 | 0% | 0 | 0% | 0 | 0.0% | 0 | 0.0% |
| **Moderate** | 0 | 0.0% | 0 | 0.0% | 0 | 0% | 0 | 0.0% | 1 | 10% | 0 | 0% | 0 | 0.0% | 0 | | 0.0% | 0 | 0% | 0 | 0% | 0 | 0.0% | 0 | 0.0% |
| **Severe** | 0 | 0.0% | 0 | 0.0% | 0 | 0% | 0 | 0.0% | 0 | 0% | 0 | 0% | 0 | 0.0% | 0 | | 0.0% | 0 | 0% | 0 | 0% | 0 | 0.0% | 0 | 0.0% |
| **Arthralgia** | **None** | 8 | 72.7% | 3 | 75.0% | 6 | 60% | 6 | 100.0% | 7 | 70% | 4 | 100% | 6 | 75.0% | 6 | | 100.0% | 5 | 50% | 4 | 100% | 5 | 62.5% | 6 | 100.0% |
| **Mild** | 3 | 27.3% | 1 | 25.0% | 2 | 20% | 0 | 0.0% | 2 | 20% | 0 | 0% | 0 | 0.0% | 0 | | 0.0% | 5 | 50% | 0 | 0% | 2 | 25.0% | 0 | 0.0% |
| **Moderate** | 0 | 0.0% | 0 | 0.0% | 2 | 20% | 0 | 0.0% | 1 | 10% | 0 | 0% | 2 | 25.0% | 0 | | 0.0% | 0 | 0% | 0 | 0% | 1 | 12.5% | 0 | 0.0% |
| **Severe** | 0 | 0.0% | 0 | 0.0% | 0 | 0% | 0 | 0.0% | 0 | 0% | 0 | 0% | 0 | 0.0% | 0 | | 0.0% | 0 | 0% | 0 | 0% | 0 | 0.0% | 0 | 0.0% |
| **Myalgia** | **None** | 10 | 90.9% | 4 | 100.0% | 8 | 80% | 6 | 100.0% | 9 | 90% | 4 | 100% | 7 | 87.5% | 6 | | 100.0% | 8 | 80% | 4 | 100% | 7 | 87.5% | 6 | 100.0% |
| **Mild** | 1 | 9.1% | 0 | 0.0% | 2 | 20% | 0 | 0.0% | 0 | 0% | 0 | 0% | 0 | 0.0% | 0 | | 0.0% | 2 | 20% | 0 | 0% | 1 | 12.5% | 0 | 0.0% |
| **Moderate** | 0 | 0.0% | 0 | 0.0% | 0 | 0% | 0 | 0.0% | 1 | 10% | 0 | 0% | 1 | 12.5% | 0 | | 0.0% | 0 | 0% | 0 | 0% | 0 | 0.0% | 0 | 0.0% |
| **Severe** | 0 | 0.0% | 0 | 0.0% | 0 | 0% | 0 | 0.0% | 0 | 0% | 0 | 0% | 0 | 0.0% | 0 | | 0.0% | 0 | 0% | 0 | 0% | 0 | 0.0% | 0 | 0.0% |
| **Feverishness** | **None** | 10 | 90.9% | 3 | 75.0% | 9 | 90% | 6 | 100.0% | 9 | 90% | 4 | 100% | 5 | 62.5% | 6 | | 100.0% | 10 | 100% | 4 | 100% | 6 | 75.0% | 5 | 83.3% |
| **Mild** | 1 | 9.1% | 1 | 25.0% | 1 | 10% | 0 | 0.0% | 1 | 10% | 0 | 0% | 0 | 0.0% | 0 | | 0.0% | 0 | 0% | 0 | 0% | 1 | 12.5% | 0 | 0.0% |
| **Moderate** | 0 | 0.0% | 0 | 0.0% | 0 | 0% | 0 | 0.0% | 0 | 0% | 0 | 0% | 1 | 12.5% | 0 | | 0.0% | 0 | 0% | 0 | 0% | 1 | 12.5% | 1 | 16.7% |
| **Severe** | 0 | 0.0% | 0 | 0.0% | 0 | 0% | 0 | 0.0% | 0 | 0% | 0 | 0% | 2 | 25.0% | 0 | | 0.0% | 0 | 0% | 0 | 0% | 0 | 0.0% | 0 | 0.0% |
| **Headache** | **None** | 7 | 63.6% | 3 | 75.0% | 7 | 70% | 6 | 100.0% | 6 | 60% | 3 | 75% | 4 | 50.0% | 4 | | 66.7% | 6 | 60% | 4 | 100% | 5 | 62.5% | 5 | 83.3% |
| **Mild** | 3 | 27.3% | 1 | 25.0% | 2 | 20% | 0 | 0.0% | 3 | 30% | 0 | 0% | 2 | 25.0% | 2 | | 33.3% | 4 | 40% | 0 | 0% | 2 | 25.0% | 0 | 0.0% |
| **Moderate** | 1 | 9.1% | 0 | 0.0% | 1 | 10% | 0 | 0.0% | 1 | 10% | 1 | 25% | 2 | 25.0% | 0 | | 0.0% | 0 | 0% | 0 | 0% | 1 | 12.5% | 1 | 16.7% |
| **Severe** | 0 | 0.0% | 0 | 0.0% | 0 | 0% | 0 | 0.0% | 0 | 0% | 0 | 0% | 0 | 0.0% | 0 | | 0.0% | 0 | 0% | 0 | 0% | 0 | 0.0% | 0 | 0.0% |
| **Fatigue** | **None** | 9 | 81.8% | 2 | 50.0% | 6 | 60% | 5 | 83.3% | 6 | 60% | 4 | 100% | 5 | 62.5% | 5 | | 83.3% | 6 | 60% | 4 | 100% | 3 | 37.5% | 6 | 100.0% |
| **Mild** | 1 | 9.1% | 2 | 50.0% | 3 | 30% | 1 | 16.7% | 3 | 30% | 0 | 0% | 2 | 25.0% | 1 | | 16.7% | 4 | 40% | 0 | 0% | 3 | 37.5% | 0 | 0.0% |
| **Moderate** | 1 | 9.1% | 0 | 0.0% | 1 | 10% | 0 | 0.0% | 1 | 10% | 0 | 0% | 1 | 12.5% | 0 | | 0.0% | 0 | 0% | 0 | 0% | 2 | 25.0% | 0 | 0.0% |
| **Severe** | 0 | 0.0% | 0 | 0.0% | 0 | 0% | 0 | 0.0% | 0 | 0% | 0 | 0% | 0 | 0.0% | 0 | | 0.0% | 0 | 0% | 0 | 0% | 0 | 0.0% | 0 | 0.0% |
| **Nausea** | **None** | 10 | 90.9% | 3 | 75.0% | 8 | 80% | 6 | 100.0% | 7 | 70% | 3 | 75% | 7 | 87.5% | 6 | | 100.0% | 8 | 80% | 4 | 100% | 7 | 87.5% | 6 | 100.0% |
| **Mild** | 1 | 9.1% | 1 | 25.0% | 2 | 20% | 0 | 0.0% | 3 | 30% | 1 | 25% | 1 | 12.5% | 0 | | 0.0% | 1 | 10% | 0 | 0% | 1 | 12.5% | 0 | 0.0% |
| **Moderate** | 0 | 0.0% | 0 | 0.0% | 0 | 0% | 0 | 0.0% | 0 | 0% | 0 | 0% | 0 | 0.0% | 0 | | 0.0% | 1 | 10% | 0 | 0% | 0 | 0.0% | 0 | 0.0% |
| **Severe** | 0 | 0.0% | 0 | 0.0% | 0 | 0% | 0 | 0.0% | 0 | 0% | 0 | 0% | 0 | 0.0% | 0 | | 0.0% | 0 | 0% | 0 | 0% | 0 | 0.0% | 0 | 0.0% |
| **Malaise** | **None** | 9 | 81.8% | 3 | 75.0% | 7 | 70% | 6 | 100.0% | 9 | 90% | 3 | 75% | 5 | 62.5% | 5 | | 83.3% | 9 | 90% | 4 | 100% | 6 | 75.0% | 5 | 83.3% |
| **Mild** | 2 | 18.2% | 1 | 25.0% | 2 | 20% | 0 | 0.0% | 1 | 10% | 1 | 25% | 1 | 12.5% | 1 | | 16.7% | 0 | 0% | 0 | 0% | 1 | 12.5% | 0 | 0.0% |
| **Moderate** | 0 | 0.0% | 0 | 0.0% | 1 | 10% | 0 | 0.0% | 0 | 0% | 0 | 0% | 2 | 25.0% | 0 | | 0.0% | 1 | 10% | 0 | 0% | 1 | 12.5% | 1 | 16.7% |
| **Severe** | 0 | 0.0% | 0 | 0.0% | 0 | 0% | 0 | 0.0% | 0 | 0% | 0 | 0% | 0 | 0.0% | 0 | | 0.0% | 0 | 0% | 0 | 0% | 0 | 0.0% | 0 | 0.0% |

**Table S1 Local and systemic solicited adverse events (AE) reported in the electronic diary card during the first seven days after each vaccination in the UK study.** *R21 was either administered alone (n=4) or mixed with Matrix-M at different doses of 2µg (n=6), 10µg (n=11) and 50µg (n=10). Only the highest intensity of each AE per subject is listed.*

|  |  |  |  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| **Event** | **Intensity** | **Vaccination 1** | | | | **Vaccination 2** | | | | **Vaccination 3** | | | |
| **10µg R21/MM** | | **Saline** | | **10µg R21/MM** | | **Saline** | | **10µg R21/MM** | | **Saline** | |
| **n (%)** | | | | **n (%)** | | | | **n (%)** | | | |
| 8 | | 5 | | 8 | | 4 | | 8 | | 4 | |
| **Pain** | **None** | 7 | 87.5% | 5 | 100.0% | 6 | 75% | 4 | 100% | 6 | 75% | 4 | 100% |
| **Mild** | 1 | 12.5% | 0 | 0.0% | 2 | 25% | 0 | 0% | 1 | 13% | 0 | 0% |
| **Moderate** | 0 | 0.0% | 0 | 0.0% | 0 | 0% | 0 | 0% | 1 | 13% | 0 | 0% |
| **Severe** | 0 | 0.0% | 0 | 0.0% | 0 | 0% | 0 | 0% | 0 | 0% | 0 | 0% |
| **Redness** | **None** | 8 | 100.0% | 5 | 100.0% | 8 | 100% | 4 | 100% | 7 | 88% | 4 | 100% |
| **Mild** | 0 | 0.0% | 0 | 0.0% | 0 | 0% | 0 | 0% | 1 | 13% | 0 | 0% |
| **Moderate** | 0 | 0.0% | 0 | 0.0% | 0 | 0% | 0 | 0% | 0 | 0% | 0 | 0% |
| **Severe** | 0 | 0.0% | 0 | 0.0% | 0 | 0% | 0 | 0% | 0 | 0% | 0 | 0% |
| **Swelling** | **None** | 8 | 100.0% | 5 | 100.0% | 7 | 88% | 4 | 100% | 6 | 75% | 4 | 100% |
| **Mild** | 0 | 0.0% | 0 | 0.0% | 0 | 0% | 0 | 0% | 0 | 0% | 0 | 0% |
| **Moderate** | 0 | 0.0% | 0 | 0.0% | 1 | 13% | 0 | 0% | 2 | 25% | 0 | 0% |
| **Severe** | 0 | 0.0% | 0 | 0.0% | 0 | 0% | 0 | 0% | 0 | 0% | 0 | 0% |
| **Fever** | **None** | 8 | 100.0% | 5 | 100.0% | 8 | 100% | 4 | 100% | 8 | 100% | 4 | 100% |
| **Mild** | 0 | 0.0% | 0 | 0.0% | 0 | 0% | 0 | 0% | 0 | 0% | 0 | 0% |
| **Moderate** | 0 | 0.0% | 0 | 0.0% | 0 | 0% | 0 | 0% | 0 | 0% | 0 | 0% |
| **Severe** | 0 | 0.0% | 0 | 0.0% | 0 | 0% | 0 | 0% | 0 | 0% | 0 | 0% |
| **Arthralgia** | **None** | 7 | 87.5% | 5 | 100.0% | 8 | 100% | 4 | 100% | 8 | 100% | 4 | 100% |
| **Mild** | 0 | 0.0% | 0 | 0.0% | 0 | 0% | 0 | 0% | 0 | 0% | 0 | 0% |
| **Moderate** | 1 | 12.5% | 0 | 0.0% | 0 | 0% | 0 | 0% | 0 | 0% | 0 | 0% |
| **Severe** | 0 | 0.0% | 0 | 0.0% | 0 | 0% | 0 | 0% | 0 | 0% | 0 | 0% |
| **Myalgia** | **None** | 8 | 100.0% | 5 | 100.0% | 8 | 100% | 4 | 100% | 8 | 100% | 4 | 100% |
| **Mild** | 0 | 0.0% | 0 | 0.0% | 0 | 0% | 0 | 0% | 0 | 0% | 0 | 0% |
| **Moderate** | 0 | 0.0% | 0 | 0.0% | 0 | 0% | 0 | 0% | 0 | 0% | 0 | 0% |
| **Severe** | 0 | 0.0% | 0 | 0.0% | 0 | 0% | 0 | 0% | 0 | 0% | 0 | 0% |
| **Feverishness** | **None** | 8 | 100.0% | 5 | 100.0% | 8 | 100% | 4 | 100% | 8 | 100% | 4 | 100% |
| **Mild** | 0 | 0.0% | 0 | 0.0% | 0 | 0% | 0 | 0% | 0 | 0% | 0 | 0% |
| **Moderate** | 0 | 0.0% | 0 | 0.0% | 0 | 0% | 0 | 0% | 0 | 0% | 0 | 0% |
| **Severe** | 0 | 0.0% | 0 | 0.0% | 0 | 0% | 0 | 0% | 0 | 0% | 0 | 0% |
| **Headache** | **None** | 7 | 87.5% | 5 | 100.0% | 8 | 100% | 4 | 100% | 7 | 88% | 4 | 100% |
| **Mild** | 0 | 0.0% | 0 | 0.0% | 0 | 0% | 0 | 0% | 0 | 0% | 0 | 0% |
| **Moderate** | 1 | 12.5% | 0 | 0.0% | 0 | 0% | 0 | 0% | 1 | 13% | 0 | 0% |
| **Severe** | 0 | 0.0% | 0 | 0.0% | 0 | 0% | 0 | 0% | 0 | 0% | 0 | 0% |
| **Fatigue** | **None** | 8 | 100.0% | 5 | 100.0% | 8 | 100% | 4 | 100% | 8 | 100% | 4 | 100% |
| **Mild** | 0 | 0.0% | 0 | 0.0% | 0 | 0% | 0 | 0% | 0 | 0% | 0 | 0% |
| **Moderate** | 0 | 0.0% | 0 | 0.0% | 0 | 0% | 0 | 0% | 0 | 0% | 0 | 0% |
| **Severe** | 0 | 0.0% | 0 | 0.0% | 0 | 0% | 0 | 0% | 0 | 0% | 0 | 0% |
| **Nausea** | **None** | 8 | 100.0% | 5 | 100.0% | 8 | 100% | 4 | 100% | 8 | 100% | 4 | 100% |
| **Mild** | 0 | 0.0% | 0 | 0.0% | 0 | 0% | 0 | 0% | 0 | 0% | 0 | 0% |
| **Moderate** | 0 | 0.0% | 0 | 0.0% | 0 | 0% | 0 | 0% | 0 | 0% | 0 | 0% |
| **Severe** | 0 | 0.0% | 0 | 0.0% | 0 | 0% | 0 | 0% | 0 | 0% | 0 | 0% |
| **Malaise** | **None** | 8 | 100.0% | 5 | 100.0% | 8 | 100% | 4 | 100% | 8 | 100% | 4 | 100% |
| **Mild** | 0 | 0.0% | 0 | 0.0% | 0 | 0% | 0 | 0% | 0 | 0% | 0 | 0% |
| **Moderate** | 0 | 0.0% | 0 | 0.0% | 0 | 0% | 0 | 0% | 0 | 0% | 0 | 0% |
| **Severe** | 0 | 0.0% | 0 | 0.0% | 0 | 0% | 0 | 0% | 0 | 0% | 0 | 0% |

**Table S2 Local and systemic solicited adverse events (AE) reported during the first seven days after each vaccination in the Burkina Faso study.** *R21 was administered mixed with Matrix-M at 10µg (n=11) and compared with saline placebo vaccination (n=5). Only the highest intensity of each AE per subject is listed.*

|  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- |
| **Symptom** | **MedDRA code** | **Intensity** | **Day of onset** | **Last day** | **Vaccination no.** | **Causality** |
| **2gR21/50g Matrix-M** | | | | | | |
| Axillary pain | 10048750 | Mild | 13 | 14 | 3 | Possible |
| Headache | 10019211 | Mild | 7 | 7 | 3 | Possible |
| Headache | 10019211 | Mild | 7 | 7 | 2 | Possible |
| Lump feeling in throat | 10051196 | Mild | 0 | 4 | 1 | Possible |
| **10gR21/50g Matrix-M** | | | | | | |
| Cough | 10011224 | Severe | 7 | 9 | 3 | Possible |
| Intestinal cramps | 10049900 | Moderate | 6 | 7 | 3 | Possible |
| Itchy | 10023089 | Mild | 11 | 11 | 1 | Possible |
| Itchy | 10023089 | Mild | 2 | 2 | 2 | Possible |
| Light headedness | 10024492 | Mild | 1 | 1 | 1 | Possible |
| Muscle spasm | 10028333 | Mild | 0 | 0 | 3 | Probable |
| Pain in jaw | 10033433 | Mild | 2 | 4 | 1 | Possible |
| Shivers | 10040559 | Mild | 6 | 6 | 3 | Possible |
| Shoulder pain | 10040617 | Mild | 0 | 0 | 1 | Definite |
| Sore throat | 10041367 | Mild | 0 | 0 | 1 | Possible |
| Sore throat | 10041367 | Severe | 7 | 9 | 3 | Possible |
| Sore throat | 10041367 | Mild | 0 | 3 | 3 | Possible |
| Stomach cramps | 10049901 | Mild | 6 | 6 | 2 | Possible |
| **50gR21/50g Matrix-M** | | | | | | |
| Chills | 10008531 | Severe | 1 | 1 | 2 | Definite |
| Injection site pain | 10022086 | Mild | 18 | 20 | 3 | Probable |
| Itchy | 10023089 | Mild | 1 | 4 | 1 | Possible |
| Localised rash | 10062705 | Mild | 2 | 4 | 1 | Probable |
| Lump feeling in throat | 10051196 | Mild | 6 | 6 | 1 | Possible |
| Rash | 10037844 | Moderate | 1 | 3 | 2 | Definite |
| Shivers | 10040559 | Mild | 1 | 1 | 2 | Definite |
| Stomach cramps | 10049901 | Mild | 0 | 0 | 1 | Possible |
| **50g R21 alone** | | | | | | |
| Stomach ache | 10042076 | Moderate | 0 | 0 | 3 | Possible |
| Itchy throat | 10053560 | Mild | 1 | 1 | 3 | Possible |
| Sore throat | 10041367 | Mild | 5 | 8 | 2 | Possible |

**Table S3 (A). Unsolicited AEs deemed definitely, probably and possibly related to vaccination reported in the 28 days following vaccination with R21 alone or adjuvanted with Matrix-M in UK participants.** *The maximum severity for each AE is shown. AEs have been classified according to the Medical Dictionary for Regulatory Activities (MedDRA) at the Lower Level (LLT) Term level.*

|  |  |  |  |
| --- | --- | --- | --- |
| **Lab AE and intensity** | **Number (% of volunteers)** | | |
| **2g R21/MM** | **Vaccination 01 (n=6)** | **Vaccination 02 (n=6)** | **Vaccination 03 (n=6)** |
| Anaemia  Grade 1 | 1 (16.7) | 0 | 0 |
| Lymphopaenia  Grade 1 | 0 | 2 (33.3) | 1 (16.7) |
| **10g R21/MM** | **Vaccination 01 (n=11)** | **Vaccination 02 (n=10)** | **Vaccination 03 (n=10)** |
| Anaemia  Grade 1 | 0 | 2 (20) | 0 |
| Neutropaenia  Grade 1 | 0 | 1 (10) | 2 (20) |
| Hypokalaemia  Grade 1 | 0 | 1 (10) | 2 (20) |
| **50g R21 alone** | **Vaccination 01 (n=4)** | **Vaccination 02 (n=4)** | **Vaccination 03 (n=4)** |
| Elevated ALT  Grade 1 | 1 (25) | 0 | 0 |
| **50g R21/MM** | **Vaccination 01 (n=10)** | **Vaccination 02 (n=8)** | **Vaccination 03 (n=8)** |
| Anaemia  Grade 1  Grade 2 | 0  0 | 2 (25)  0 | 0  1 (12.5) |
| Low WBC  Grade 1 | 1 (10) | 0 | 1 (12.5) |
| Lymphopaenia  Grade 1 | 1 (10) | 0 | 0 |
| Elevated Urea  Grade 1 | 0 | 0 | 1 (12.5) |

**Table S4. Frequency of all laboratory adverse events following vaccination with R21 alone or adjuvanted with Matrix-M in UK cohort.** *Adverse events are defined as a deviation from the baseline result collected pre-vaccination on Day 0.*

|  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- |
| **Symptom** | **Intensity** | **Day of onset** | **Duration (Days)** | **Vaccination no.** | **Causality** |
| **10g R21/MM** | | | | | |
| Rhinitis | Moderate | 20 | 3 | 1 | No relationship |
| Bronchitis | Moderate | 20 | 5 | 1 | No relationship |
| Enteritis | Moderate | 19 | 4 | 1 | No relationship |
| Epigastralgia | Moderate | 5 | 9 | 2 | No relationship |
| Ocular hyperhemia | Moderate | 84 | 7 | 3 | No relationship |
| Bronchitis | Moderate | 8 | 8 | 2 | No relationship |
| Epididymitis | Moderate | 8 | 8 | 2 | No relationship |
| Furuncle on the left leg | Moderate | 17 | 22 | 2 | No relationship |
| Bronchitis | Moderate | 80 | 14 | 3 | No relationship |
| Sore throat | Moderate | 23 | 12 | 3 | No relationship |
| Rhinitis | Moderate | 18 | 3 | 1 | No relationship |
| Bronchitis | Moderate | 23 | 8 | 1 | No relationship |
| Epigastralgia | Moderate | 27 | 7 | 3 | No relationship |
| Teeth decay | Moderate | 10 | 8 | 1 | No relationship |
| Conjunctivitis | Moderate | 3 | 14 | 1 | No relationship |
| Headache | Moderate | 10 | 1 | 1 | No relationship |
| Rhinitis | Moderate | 6 | 2 | 2 | No relationship |
| Furuncle | Moderate | 4 | 30 | 1 | No relationship |
| **Normal saline placebo** | | | | | |
| Conjunctivitis | Moderate | 5 | 6 | 2 | No relationship |
| Epigastralgia | Moderate | 27 | 5 | 3 | No relationship |
| Epigastralgia | Moderate | 83 | 6 | 3 | Unlikely |

**Table S5:****Unsolicited AEs reported in the 28 days following vaccination with R21 alone or adjuvanted with Matrix-M in Burkinabe participants.** *The maximum severity for each AE is shown. AEs have been classified according to the DAIDS AE grading table, published in 2004.*

|  |  |  |  |
| --- | --- | --- | --- |
| **Lab AE and intensity** | **Number (% of volunteers)** | | |
| **10µg R21/MM** | **Vaccination 01 (n=8)** | **Vaccination 02 (n=8)** | **Vaccination 03 (n=8)** |
| Anaemia  Grade 1 | 1 (12.5) | 1(12.5) | 1(12.5) |
| Neutropaenia  Grade 1 | 3 (37.5) | 3(37.5) | 3(37.5) |
| Neutropaenia  Grade 2 | 2 (25) | 2(25) | 0 |
| Neutropaenia  Grade 3 | 1(12.5) | 0 | 0 |
| Elevated Creatinine  Grade 3 | 0 | 0 | 1(12.5) |
| **Normal saline placebo** | **Vaccination 01 (n=5)** | **Vaccination 02 (n=5)** | **Vaccination 03 (n=5)** |
| Anaemia  Grade 2 | 1 (20) | 1(20) | 0 |
| Neutropaenia  Grade 1 | 1(20) | 1(20) | 2(40) |
| Neutropaenia  Grade 2 | 1(20) | 1(20) | 1(20) |
| Elevated Creatinine  Grade 3 | 1(20) | 1(20) | 1(20) |
| Elevated ALT  Grade 3 | 1(20) | 1(20) | 1(20) |

**Table S6. Frequency of all laboratory adverse events following vaccination with R21 adjuvanted with Matrix-M or normal saline in the Burkinabe cohort.** *Adverse events are defined as a deviation from the baseline result collected pre-vaccination on Day 0. AEs have been classified according to the DAIDS AE grading table, published in 2004.*